Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBright Minds Biosciences Inc

Bright Minds Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
26.0 CAD -0.11 ( 0.42%)
Last update at 2026-11-05T14:43:00Z
VOLUME
202
Market Cap
1152.73M

Momentum Score

…

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
26.00
Low
26.00
High
52 Week Price Range
33.01
Low
170.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bright Minds Biosciences Inc is a Canada-listed biotech developing small-molecule therapeutics inspired by psychedelic compounds to treat mental health and neurological disorders; its programs are at preclinical and early clinical stages. Long-term growth drivers include growing scientific and regulatory acceptance of psychedelic-derived treatments, pipeline progression, and potential partnerships or licensing, so investors may find exposure to an emerging therapeutic area attractive.
Key risks include high clinical and regulatory failure risk, significant financing needs, and uncertainty around market access.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
26.11
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-26.98%
Net Debt
-
ROCE
-16.98%
Diluted EPS TTM
-2.76

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -12.23M -2.80M -7.37M -14.96M -8.65M
Net income -12.23M -2.80M -7.37M -14.96M -8.65M
Selling general administrative 2.57M 1.45M 2.20M 2.55M 2.47M
Reconciled depreciation 0.08M 0.07M 0.07M 0.01M 0.00M
Ebit - - - -14.73M -8.79M
Ebitda - - - -14.73M -
Operating income -13.94M -2.82M -7.39M -14.73M -8.79M
Interest expense - - - - 0.00M
Interest income 1.52M 0.03M 0.00M 0.00M -
Net interest income 1.52M 0.03M 0.00M 0.00M -0.02M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 13.94M 2.82M 7.39M 14.73M 8.79M
Total other income expense net 0.19M -0.01M 0.01M -0.23M 0.15M
Net income from continuing ops -12.23M -2.80M -7.37M -14.96M -8.65M
Net income applicable to common shares - - - -14.96M -8.65M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 84.42M 6.10M 6.88M 12.09M 20.04M
Total liab 2.38M 0.57M 0.28M 1.54M 0.64M
Total stockholder equity 82.04M 5.54M 6.60M 10.54M 19.40M
Common stock - - - 32.24M 27.08M
Capital stock 123.25M 35.42M 33.91M 32.24M 27.08M
Retained earnings -46.58M -34.35M -31.55M -24.17M -9.21M
Cash 82.91M 5.72M 6.75M 11.63M 19.76M
Total current liabilities 2.34M 0.53M 0.28M 1.47M 0.64M
Other stockholder equity - - - 2.48M 1.53M
Property plant equipment - - - 0.14M -
Total current assets 84.31M 5.99M 6.81M 11.95M 20.04M
Net tangible assets - - - 10.54M 19.40M
Net receivables - - - 0.16M 0.11M
Accounts payable 1.71M 0.41M 0.18M 1.25M 0.60M
Non current assets total 0.11M 0.12M 0.07M 0.14M 0.00M
Capital lease obligations 0.13M 0.12M 0.07M 0.14M 0.00M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Change to liabilities - - - 0.77M 0.51M
Net borrowings -0.10M -0.09M -0.09M -0.01M -0.01M
Total cash from financing activities 85.57M 0.81M 2.19M 5.20M 26.06M
Change to operating activities - - - -0.04M -0.20M
Net income -12.23M -2.80M -7.37M -14.96M -8.65M
Change in cash 76.88M -1.04M -4.83M -8.13M 18.96M
Begin period cash flow 5.72M 6.75M 11.63M 19.76M 0.80M
End period cash flow 82.91M 5.72M 6.75M 11.63M 19.76M
Total cash from operating activities -8.69M -1.85M -7.02M -13.59M -7.32M
Issuance of capital stock 82.10M 0.90M 1.22M 4.03M 27.74M
Depreciation 0.08M 0.07M 0.07M 0.01M 0.01M
Other cashflows from financing activities - - - -0.80M -1.79M
Change to netincome - - - 0.65M 1.03M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.55M 0.04M -0.94M 0.73M 0.31M
Stock based compensation 3.18M 0.84M 1.15M 0.88M 0.88M
Other non cash items 0.04M 0.01M 0.02M 0.03M 0.37M
Free cash flow -8.69M -1.85M -7.02M -13.59M -7.32M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
DRUG
Bright Minds Biosciences Inc		 -0.11
0.42%		 26.00 - - - 13.50 -0.10
METX
ME Therapeutics Holdings Inc.		 -
-%		 1.05 - - - 72.00 -
TELI
Telescope Innovations Corp.		 -0.01
1.56%		 0.32 - - 4.32 6.45 -1.62
DTC
Defence Therapeutics Inc		 0.01
4.48%		 0.35 - - - 89.80 -9.99
LOBE
Lobe Sciences Ltd		 -0.01
12.50%		 0.04 - - 2.44 15.58 1.64

Profile*

Bright Minds Biosciences Inc

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

19 Vestry Street, New York, NY, United States, 10013

647 865 8622

https://brightmindsbio.com

26

Name Title Year Born
Mr. Ian McDonald Co-Founder, CEO, President & Director 1988
Dr. Jan Torleif Pedersen M.Sc., Ph.D. Chief Science Officer & Director 1965
Mr. Alex Vasilkevich COO & Senior Scientific Officer 1988
Dr. Emer Leahy M.B.A., Ph.D. Consultant 1967
Dr. Stephen D. Collins M.D., Ph.D. Chief Medical Officer 1952
Mr. Alex Vasilkevich COO & Senior Scientific Officer 1989
Dr. Stephen D. Collins M.D., Ph.D. Chief Medical Officer 1953

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
TOI
CAD 103.80
+7.09%
CRON
CAD 5.26
+6.69%
CIA
CAD 2.04
+6.25%
ITH
CAD 1.61
-34.02%
IFOS
CAD 1.65
-22.90%
TNZ
CAD 49.70
-19.58%
KEEL
CAD 2.36
-19.45%
GIL
CAD 49.36
-18.33%

Equity Sectors*

  • Basic Materials

    -2.18%

  • Communication Services

    +0.95%

  • Consumer Cyclical

    -2.25%

  • Consumer Defensive

    -0.68%

  • Energy

    -2.93%

  • Financial Services

    -2.26%

  • Healthcare

    -0.46%

  • Industrials

    -3.70%

  • Real Estate

    -0.06%

  • Technology

    -3.32%

  • Utilities

    -0.50%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…